Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Halozyme: Reading the News While Keeping Our Focus on the Promises

January 27, 2016 0

Halozyme Therapeutics (HALO) seems to have closed the previously announced $150 million royalty-backed debt transaction with investment …

Theravance Biopharma: Launching Vibativ in Canada for MRSA

January 26, 2016 0

Theravance Biopharma (TBPH) announced the commercial launch of VIBATIV® (telavancin) in Canada. VIBATIV is a once-daily antibiotic …

Revolutionary Approaches Towards Managing Chronic and Deadly Diseases

January 22, 2016 0

The Market is Surely Ignoring the Historical Summit Biotech achievements are standing on Right Now …

OIL: A Blessing or a Curse? It Depends on What Some Want it to Be

January 20, 2016 0

Escaping the slaughter, or taking advantage of it, or accumulating the stocks we love, or turning …

Prohost Letter #390

January 15, 2016 0

Prohost Letter #390 COMPANIES USING CRISPR GENE EDITING TOOLS - The Firms Launched with CRISPR Patents Either …

Of the Biotech Sector Selloff. Spark Presents its Current and Future Programs

January 12, 2016 0

Of the Biotech Sector’s Selloff Testing the lows in biotech firms’ stock prices is nothing but …

The Two Pianists: Breakthrough in the Diagnosis and Treatment of Diseases. See Also: Illumina

January 11, 2016 0

The Evolution of Liquid Biopsy TWO PIANISTS, GUARDANT HEALTH and C4 THERAPEUTICS Biotech firms are bringing …

Steps Forward in the Management of Inflammatory and Autoimmune Diseases

January 8, 2016 0

Improving the management of inflammatory and autoimmune diseases has been a dream that seems to be …

Exelixis Has Good News

January 5, 2016 0

Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib …

How Far Can the Market Go in Ignoring Gilead?

January 5, 2016 0

On Oct. 28, 2015, Gilead Sciences (GILD) announced that it has submitted a New Drug Application …

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

January 4, 2016 0

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. …

Prohost Letter #389

January 2, 2016 0

Prohost Letter #389 Happy New Year 2016 Wishing You Good Health Peace of Mind Love And …

Array Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

December 16, 2015 0

When you do your due diligence, you do not lose your faith in what you believed …

Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer

December 10, 2015 0

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …

Xoma: Good News for the Firm We Love and Hate But We Never Divorce

December 2, 2015 0

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes – Novo Nordisk acquires …

Prohost Letter #388

December 2, 2015 0

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY …

BioMarin: What Happened During the FDA Committee Meeting?

November 25, 2015 0

In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin …

BioMarin: The DMD Drug and the FDA Committee Options

November 24, 2015 0

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released …

Vertex: Orkambi Approved In Europe. What Vertex Is Doing to Further improve CF Treatments

November 20, 2015 0

Europe Approves Orkambi® The European Commission has granted Marketing Authorization for Orkambi® (lumacaftor/ivacaftor), for cystic fibrosis …

Ziopharm Wages Its Own War on Brain Cancer

November 19, 2015 0

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Halozyme: Reading the News While Keeping Our Focus on the Promises

Theravance Biopharma: Launching Vibativ in Canada for MRSA

Revolutionary Approaches Towards Managing Chronic and Deadly Diseases

OIL: A Blessing or a Curse? It Depends on What Some Want it to Be

Prohost Letter #390

Of the Biotech Sector Selloff. Spark Presents its Current and Future Programs

The Two Pianists: Breakthrough in the Diagnosis and Treatment of Diseases. See Also: Illumina

Steps Forward in the Management of Inflammatory and Autoimmune Diseases

Exelixis Has Good News

How Far Can the Market Go in Ignoring Gilead?

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

Prohost Letter #389

Array Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer

Xoma: Good News for the Firm We Love and Hate But We Never Divorce

Prohost Letter #388

BioMarin: What Happened During the FDA Committee Meeting?

BioMarin: The DMD Drug and the FDA Committee Options

Vertex: Orkambi Approved In Europe. What Vertex Is Doing to Further improve CF Treatments

Ziopharm Wages Its Own War on Brain Cancer